
    
      This is a Phase 3, parallel group, multicenter, rollover study in participants with CF who
      are homozygous or heterozygous for the F508del CFTR mutation and who previously participated
      in Study 103 (Study VX12-809-103, NCT01807923), Study 104 (Study VX12-809-104, NCT01807949),
      or Cohort 4 of Study 102 (Study VX09-809-102, NCT01225211).
    
  